Your browser doesn't support javascript.
Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?
Spinetti, Gaia; Avolio, Elisa; Madeddu, Paolo.
  • Spinetti G; IRCCS MultiMedica, Milan 20138, Italy.
  • Avolio E; Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol BS2 8HW, UK.
  • Madeddu P; Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol BS2 8HW, UK.
Regen Med ; 16(5): 477-494, 2021 05.
Article in English | MEDLINE | ID: covidwho-1229139
ABSTRACT
In many countries, COVID-19 now accounts for more deaths per year than car accidents and even the deadliest wars. Combating the viral pandemics requires a coordinated effort to develop therapeutic protocols adaptable to the disease severity. In this review article, we summarize a graded approach aiming to shield cells from SARS-CoV-2 entry and infection, inhibit excess inflammation and evasion of the immune response, and ultimately prevent systemic organ failure. Moreover, we focus on mesenchymal stem cell therapy, which has shown safety and efficacy as a treatment of inflammatory and immune diseases. The cell therapy approach is now repurposed in patients with severe COVID-19. Numerous trials of mesenchymal stem cell therapy are ongoing, especially in China and the USA. Leader companies in cell therapy have also started controlled trials utilizing their quality assessed cell products. Results are too premature to reach definitive conclusions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells / Cell- and Tissue-Based Therapy / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Regen Med Year: 2021 Document Type: Article Affiliation country: Rme-2020-0189

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mesenchymal Stem Cell Transplantation / Mesenchymal Stem Cells / Cell- and Tissue-Based Therapy / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Regen Med Year: 2021 Document Type: Article Affiliation country: Rme-2020-0189